• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease.

作者信息

Saadeh Michael, Chandar Apoorva Krishna, Al-Kindi Sadeer, Nguyen Vu Quang, Baskin Revital Gorodeski, Katz Jeffry, Cominelli Fabio, Regueiro Miguel, Mansoor Emad

机构信息

Internal Medicine, Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, United States.

Digestive Health Institute, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.

出版信息

Crohns Colitis 360. 2025 Aug 12;7(3):otaf056. doi: 10.1093/crocol/otaf056. eCollection 2025 Jul.

DOI:10.1093/crocol/otaf056
PMID:40919598
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12409399/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ab/12409399/7441dbdd9fe9/otaf056f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ab/12409399/7441dbdd9fe9/otaf056f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/41ab/12409399/7441dbdd9fe9/otaf056f1.jpg

相似文献

1
Effect of glucagon-like peptide-1 receptor agonists on major adverse cardiovascular events in patients with inflammatory bowel disease.胰高血糖素样肽-1受体激动剂对炎症性肠病患者主要不良心血管事件的影响。
Crohns Colitis 360. 2025 Aug 12;7(3):otaf056. doi: 10.1093/crocol/otaf056. eCollection 2025 Jul.
2
Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes.用于慢性肾病和糖尿病患者的胰高血糖素样肽1（GLP-1）受体激动剂。
Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849. doi: 10.1002/14651858.CD015849.pub2.
3
Glucagon-like peptide-1 receptor agonists are associated with fewer major adverse cardiovascular and limb events in patients with moderate peripheral arterial disease.胰高血糖素样肽-1受体激动剂与中度外周动脉疾病患者较少的主要不良心血管和肢体事件相关。
J Vasc Surg. 2025 Jun 6. doi: 10.1016/j.jvs.2025.05.037.
4
The quantity, quality and findings of network meta-analyses evaluating the effectiveness of GLP-1 RAs for weight loss: a scoping review.评估胰高血糖素样肽-1受体激动剂（GLP-1 RAs）减肥效果的网状Meta分析的数量、质量及结果：一项范围综述
Health Technol Assess. 2025 Jun 25:1-73. doi: 10.3310/SKHT8119.
5
Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight: an updated systematic review and network meta-analysis of randomized controlled trials.七种胰高血糖素样肽-1 受体激动剂和多激动剂在肥胖或超重患者中的减肥作用：一项更新的随机对照试验的系统评价和网络荟萃分析。
Metabolism. 2024 Dec;161:156038. doi: 10.1016/j.metabol.2024.156038. Epub 2024 Sep 19.
6
Effect of glucagon-like peptide 1 receptor agonists on the renal protection in patients with type 2 diabetes: A systematic review and meta-analysis.胰高血糖素样肽 1 受体激动剂对 2 型糖尿病患者肾脏保护作用的系统评价和 Meta 分析。
Diabetes Metab. 2022 Sep;48(5):101366. doi: 10.1016/j.diabet.2022.101366. Epub 2022 Jun 24.
7
Safety and Effectiveness of Glucagon-like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease.胰高血糖素样肽-1受体激动剂在炎症性肠病中的安全性和有效性
Am J Gastroenterol. 2025 May 1;120(5):1152-1155. doi: 10.14309/ajg.0000000000003208. Epub 2024 Nov 14.
8
Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.2型糖尿病患者中胰高血糖素样肽-1受体激动剂心血管安全性的最新进展。一项随机对照试验的混合治疗比较荟萃分析。
Heart Lung Circ. 2018 Nov;27(11):1301-1309. doi: 10.1016/j.hlc.2018.03.018. Epub 2018 Mar 29.
9
Glucagon-Like Peptide 1 Receptor Agonists Are Not Associated With an Increased Risk of Ileus or Intestinal Obstruction in Patients with Inflammatory Bowel Disease-A Danish Nationwide Cohort Study.胰高血糖素样肽-1受体激动剂与炎症性肠病患者肠梗阻或肠阻塞风险增加无关——一项丹麦全国队列研究
Inflamm Bowel Dis. 2025 Jul 7;31(7):1961-1965. doi: 10.1093/ibd/izae276.
10
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.钠-葡萄糖共转运蛋白 2（SGLT-2）抑制剂和胰高血糖素样肽-1（GLP-1）受体激动剂治疗 2 型糖尿病：随机对照试验的系统评价和网络荟萃分析。
BMJ. 2021 Jan 13;372:m4573. doi: 10.1136/bmj.m4573.

本文引用的文献

1
Cardiovascular Comorbidities and Inflammatory Bowel Disease: Causes and Consequences.心血管合并症与炎症性肠病：病因与后果
Gastroenterol Hepatol (N Y). 2024 Apr;20(4):204-215.
2
Performance of ASCVD Risk Prediction Models in Individuals With Inflammatory Bowel Disease: A UK Biobank Study.炎症性肠病患者中动脉粥样硬化性心血管疾病（ASCVD）风险预测模型的性能：一项英国生物银行研究
Inflamm Bowel Dis. 2025 Jan 6;31(1):285-289. doi: 10.1093/ibd/izae007.
3
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.司美格鲁肽在肥胖但无糖尿病患者中的心血管结局。
N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11.
4
Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent.胰高血糖素样肽-1：一种多效抗炎剂。
Front Immunol. 2023 May 17;14:1148209. doi: 10.3389/fimmu.2023.1148209. eCollection 2023.
5
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.GLP-1 受体激动剂的抗炎和免疫特性。
Pharmacol Res. 2022 Aug;182:106320. doi: 10.1016/j.phrs.2022.106320. Epub 2022 Jun 20.
6
Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?炎症性肠病与心血管疾病风险：所有炎症都会导致心脏病吗？
Trends Cardiovasc Med. 2020 Nov;30(8):463-469. doi: 10.1016/j.tcm.2019.10.001. Epub 2019 Oct 11.
7
Risk of Myocardial Infarction in Inflammatory Bowel Disease: A Population-based National Study.炎症性肠病患者心肌梗死的风险：一项基于人群的全国性研究。
Inflamm Bowel Dis. 2019 May 4;25(6):1080-1087. doi: 10.1093/ibd/izy354.
8
Increased Risk of Acute Myocardial Infarction and Heart Failure in Patients With Inflammatory Bowel Diseases.炎症性肠病患者发生急性心肌梗死和心力衰竭的风险增加。
Clin Gastroenterol Hepatol. 2018 Oct;16(10):1607-1615.e1. doi: 10.1016/j.cgh.2018.04.031. Epub 2018 Apr 24.
9
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.司美格鲁肽与 2 型糖尿病患者的心血管结局
N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15.
10
Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis.炎症性肠病患者发生脑血管意外和缺血性心脏病的风险：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2014 Mar;12(3):382-93.e1: quiz e22. doi: 10.1016/j.cgh.2013.08.023. Epub 2013 Aug 24.